



The Nifty previous session ended 0.94% down at 14,496.50. It opened on a positive note and got sold off from day's high towards finishing off in red with a bearish body candle. Critical resistance placed around 14,700 remained unharmed. It may continue trading range-bound in the price range of 14,700-14,440, as discussed earlier.

On the Nifty hourly chart; failed to sustain above the critical MA band. Direction of the leading indicators suggests critical MA band centric oscillation. Downside is limited till 14,300 levels as of now.

Nifty patterns on multiple time frames suggest; range-bound oscillation in the price band of 14,700-14,440 to continue. The benchmark index might be heading back to 14,300 levels if it fails to hold 14,440.

Nifty Crucial Supports & Resistances-

Supports- 14440, 14300 Resistances- 14700, 14900

Open Positional Calls-

T+5 Positional Buy-
|Cash Segment| GLENMARK @ 557-555, TGT- 595, Closing SL- 535

BTST Positional Buy-
|Cash Segment| CANARA BANK @ 140.50-140, TGT- 146, Closing SL- 137

T+3 Positional Buy-
|Cash Segment| INDIAN BANK @ 113-112, TGT- 122, Closing SL- 107

BTST Positional Buy-
|Cash Segment| SBIN @ 352-350, TGT- 360, Closing SL- 345

Key Contents	Page No.
Result Update	4
Domestic News	5

Nifty Intraday Chart



Market in Retrospect

India stocks ended lower as the country continues to witness a persistent increase in the daily caseload of coronavirus, forcing investors to weigh the chances of the government announcing a nationwide lockdown to control the situation.

Nifty index ended 0.94% lower at 14,497. The broader markets represented by the NIFTY 500 Index ended 0.76% higher, ending at 12,300. Among the sectorial indices, NIFTY PSU Bank was the top gainer, gaining by 3.44%, followed by NIFTY PSE, gaining by 0.56% higher. NIFTY Pharma was the top loser, losing by 2.02%.

SBI Life was the top gainer, gaining by 2.53%, followed by ONGC and BPCL which gained by 1.81% & 1.31% respectively. Tata Consumer Products was the top loser, losing by 4.70%, followed by Cipla and Dr. Reddy's, which fell by 3.49% & 2.29% respectively.

The Advance : Decline ratio stood at 778:1136

Market Turnover (In Crore) 04-05-2021

Name	Last	Previous
NSE Cash	*NA	70782.43
NSE F&O	3728946.94	3048844.96
BSE Cash	5,963.51	4,691.11
BSE F&O	*NA	104.35

FII Derivatives Flow (In Crore) 03-05-2021*

Instrument	Purchase	Sale	Net
Index Future	4331.36	6247.29	1915.93
Index Option	347358.90	344559.74	2799.16
Stock Future	13307.28	13500.63	193.35
Stock Option	12481.16	12516.70	35.54

Institutional Flow (In Crore) 03-05-2021*

Institution	Purchase	Sale	Net
FII	4273.18	6562.64	2289.46
DII	4366.26	3813.34	552.92

*Data not updated till 5:30pm

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
SBI Life Insurance	2.53	5.83	10515809	2282788
ONGC	1.81	6.25	30811922	29219580
BPCL	1.31	0.26	9993939	9370873
Bajaj Finance	1.16	15.43	4838347	5327683
Adani Ports & SE	0.97	2.62	31400296	16827300

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
RIL	2.17	3.62	10083693	9045076
Divi'S Laboratories	2.18	1.95	492286	1176575
Dr. Reddy'S	2.29	0.20	795618	1023714
Cipla	3.49	3.72	8347795	6132606
Tata Consumer Prd	4.70	4.22	7400792	2719759

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	48253.51	465.01	0.95	1.41	3.55	4.66	52.15
Nifty	14496.50	137.65	0.94	1.07	2.49	2.68	55.99
BSE M Cap	20220.07	102.42	0.50	0.30	1.44	3.19	75.79
BSE S Cap	21885.69	125.45	0.57	1.76	3.86	14.29	103.52
Nifty MC 100	24167.80	95.70	0.39	0.50	0.21	6.59	87.23
BSE Auto	21493.55	218.42	1.01	1.56	4.86	12.38	72.90
BSE Capgoods	20384.33	11.66	0.06	0.86	4.96	6.57	76.00
BSE FMCG	12612.65	63.41	0.50	0.09	1.98	0.83	21.86
BSE Metal	17965.35	117.22	0.65	5.84	18.76	46.82	190.19
BSE Oil&Gas	14989.74	107.32	0.72	1.76	0.64	1.54	29.32
BSE Healthcare	23325.51	356.36	1.50	0.08	8.35	7.83	51.81
BSE Power	2505.74	6.31	0.25	1.46	1.49	12.54	73.17
BSE Realty	2436.44	12.95	0.53	2.45	9.03	9.37	80.43
BSE ConsDur	31329.26	350.92	1.11	3.06	4.51	1.24	64.35
BSE Bank	36758.38	211.89	0.57	1.08	3.87	7.97	62.04
BSE IT	26135.44	191.10	0.73	1.18	2.37	1.87	93.12

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.62	0.02	1.34	0.16	5.96	42.12	155.52
UK	0.85	0.01	1.07	9.95	7.04	93.41	268.40
Brazil	3.98	0.02	0.58	0.10	6.45	15.85	12.06
Japan	0.10	0.00	0.00	14.12	23.02	59.02	610.53
Australia	1.76	0.01	0.34	1.27	4.45	43.12	111.42
India	6.02	0.01	0.23	0.76	2.45	0.97	1.12
Switzerland	0.18	0.03	13.94	28.11	41.69	50.55	64.63
Germany	0.20	0.01	4.41	21.69	40.55	57.05	65.36

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	73.86	0.08	0.10	1.08	0.76	1.22	2.53
USD Index	91.31	0.36	0.40	0.44	1.75	0.24	8.22
YUAN	6.47	0.00	0.04	0.33	1.20	0.11	9.09
GBP	1.39	0.00	0.20	0.22	0.12	1.54	11.57
EUR	1.20	0.01	0.43	0.65	1.68	0.40	10.13
YEN	109.40	0.33	0.30	0.64	0.71	3.53	2.43

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	3053.00	46.00	1.53	9.51	47.35	130.07	394.81
Baltic Dirty	606.00	1.00	0.17	0.50	13.30	21.93	45.16
SG Dubai HY	1.45	0.20	12.12	2.68	935.71	43.56	68.60

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34113.23	238.38	0.70	0.39	2.90	9.84	43.64
Nasdaq	13895.12	67.56	0.48	1.72	3.08	0.85	59.52
S&P 500	4192.66	11.49	0.27	0.12	4.30	8.29	47.49
FTSE100	7020.93	51.38	0.74	0.83	4.21	7.89	21.83
CAC40	6344.03	35.83	0.57	1.12	3.95	13.11	44.89
DAX	15198.31	36.66	0.24	0.32	0.61	8.10	45.22
Mexico IPC	48498.64	488.92	1.02	0.87	2.65	9.81	33.35
Brazil Bovespa	119209.5	315.70	0.27	1.15	3.43	0.04	51.13
Russian RTS	1509.67	23.78	1.60	0.69	2.87	8.78	34.11
Japan Nikkei	28812.63	241.34	0.83	1.29	3.49	0.58	46.86
Hang Seng	28557.14	199.60	0.70	1.33	1.32	1.91	20.93
Taiwan Index	16933.78	288.57	1.68	3.63	2.19	7.82	57.96
Shanghai Comp	3446.86	28.05	0.81	0.79	1.08	2.00	20.52
KOSPI	3147.37	20.17	0.64	2.12	1.11	1.94	66.06
Malaysia KLCI	1588.25	2.48	0.16	2.17	0.18	0.21	15.38
Jakarta Comp	5963.82	11.22	0.19	0.07	0.79	2.35	29.49
Philippine SE	6359.15	10.13	0.16	0.04	1.30	7.89	14.13
Thai Exch	1583.13	7.33	0.46	1.90	0.82	6.84	21.62

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	65.63	1.10	1.71	4.21	6.74	16.65	221.68
BRENT Crude	68.84	1.24	1.84	4.45	6.73	19.07	92.61
Natural Gas	2.95	0.02	0.61	0.20	9.31	0.20	12.26

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1783.09	9.74	0.54	0.37	3.14	0.61	4.76
Silver(\$/Ounce)	26.76	0.14	0.52	1.89	7.02	1.57	81.11
Aluminium	2407.50	13.75	0.57	2.02	10.06	21.48	65.01
Copper	9829.00	60.00	0.61	2.58	11.85	25.01	90.48
Zinc	2913.25	9.00	0.31	2.63	3.85	13.95	50.60
Lead	2137.00	38.75	1.85	4.93	9.45	6.40	32.71

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	141.30	1.05	0.75	3.15	14.37	10.30	23.24
Cotton	87.71	0.15	0.17	4.06	10.65	1.74	48.13
Sugar	17.09	0.36	2.15	3.72	16.10	15.55	51.24
Wheat	720.00	2.00	0.28	1.74	17.94	14.65	35.40
Soybean	1534.00	10.00	0.66	0.95	9.83	13.67	80.79

Alembic Pharmaceuticals

Alembic Pharmaceuticals reported consolidated net profit jumped 12% to INR251 crore on 6% increase in net sales to INR1,280 crore in Q4 FY21 over Q4 FY20. On a consolidated basis, the company's net profit jumped 42% to INR1178 crore on 17% increase in net sales to INR5393 crore in the year ended March 2021 over the year ended March 2020. International formulations jumped 19% Y-o-Y (year-on-year) to INR2,942 crore in FY21 over FY20. US Generics spurted 9% Y-o-Y to INR2,163 crore in FY21 over FY20. Ex-US International Formulations soared 57% Y-o-Y to INR779 crore in FY21. 13 ANDA's were filed in the quarter and 29 ANDA filings for the year. India branded formulations business grew 5% to INR1,497 crore in FY21 from FY20. API business grew 38% Y-o-Y to INR214 crore in the quarter and 35% Y-o-Y to INR955 crore in FY21 over FY20.

DCM Shriram

DCM Shriram reported 14.26% yoy growth in consolidated sales revenues for the Mar-21 quarter at Rs2,190.56cr. There was growth in two of its largest verticals. The Chloro-Vinyl vertical saw total sales up 29.5% at Rs627.06cr while revenues of the sugar vertical was up 21.8% at Rs1,020.67cr. However, revenues were flat, up just 1.47% on sequential basis. The consolidated operating profits were up 6.78% at Rs302.34cr. This sharp rise in operating profit could be attributed to a sharp reduction in the raw material costs. The OPM actually tapered from 14.77% in the Mar-20 quarter to 13.80% in Mar-21 quarter. OPM was lower on a sequential basis from 16.13% in Dec-20 quarter. The consolidated Profit after tax (PAT) for the Mar-21 quarter improved by 15.13% to Rs231.72cr. The EBITDA growth in the quarter was driven by the Chloro-Vinyl vertical. In the Mar-21 quarter, the largest sugar vertical saw EBIT up 13.4% at Rs220.64cr. However, the Chloro-Vinyl business saw EBIT up 117% at Rs176cr, which triggered the profit growth.

Suven Life Sciences

Suven Life Sciences reported a consolidated net loss of INR21.69 crore in Q4 FY21 compared with net loss of INR25.74 crore in Q4 FY20. Total income during the quarter tumbled 75.3% year-on-year to INR2.88 crore. R&D and operational expense declined 31.4% to INR23.13 crore in Q4 FY21 over Q4 FY20. On a consolidated basis, the company reported a net loss of INR72.45 crore in the year ended 31 March 2021 compared with net loss of INR94.51 crore the year ended 31 March 2020. Total income fell 25.4% to INR21.23 crore in FY21 over FY20.

L&T Technology

Net Sales at INR1,440.50 crore in March 2021 down 0.42% from INR1,446.60 crore in March 2020. Quarterly Net Profit at INR194.50 crore in March 2021 down 5.03% from INR204.80 crore in March 2020. EBITDA stands at INR327.70 crore in March 2021 down 0.61% from INR329.70 crore in March 2020. L&T Technology EPS has decreased to INR18.54 in March 2021 from INR19.61 in March 2020.

Gautam Solar installs 1,000 solar pumps in Haryana

Gautam Solar has installed solar pumps at 1,000 different locations for farmers in Haryana under the Pradhan Mantri Kusun Yojana. The government has set a target of installing 15,000 solar pumps in Haryana within the first year of the scheme which aims at reducing farmers' reliance on diesel-based generators and make it easier for them to access electricity. The company has installed solar pumps of 10 HP capacity at 1,000 different locations in Haryana under the PM Kusun Yojana. The scheme was launched by the Ministry of New and Renewable Energy (MNRE) in 2019. It seeks to provide subsidies on solar pumps to farmers. Under this scheme, farmers have to bear 40 per cent of the pump's cost, while the central and state governments subsidize the remaining 60 per cent for solar pumps that have a capacity of up to 10 HP.

Anupam Rasayan to invest INR43 cr to set up a 12.5 MW solar power plant

Speciality chemical company Anupam Rasayan India will invest INR43 crore to set up a 12.5 megawatt (MW) solar power plant. In a conscious move towards reducing dependence on non-renewable energy and cost saving measure, Anupam Rasayan has issued a letter of intent to install solar power by investing a sum of INR43 crore. The company is the entire capital expenditure of INR43 crore will be funded from its IPO proceeds. The size of the proposed solar power plant will be 12.5 MW and will cater to the energy requirements of Anupam Rasayan's major units.

Petrol, diesel prices rise again after 18 days of no change

Fuel prices in India were hiked on Tuesday after 18 consecutive days of no price revision. In Delhi, petrol prices rose by 15 paise to INR90.55 a litre. In Mumbai, prices went up by 12 paise to INR96.95, in Chennai by 12 paise to INR92.55 a litre, and in Kolkata by 14 paise to INR90.76. For diesel, Delhi pump prices went up by 18 paise to INR80.91 a litre. In Mumbai it rose by 17 paise to INR87.98, in Chennai by 15 paise to INR85.90 and in Kolkata by 17 paise to INR83.78. The last fuel price movement in India was on April 15 when petrol prices had come down by 16 paise and diesel by 14 paise. Before that fall, prices had been kept static for two weeks.

Mphasis to set up nearshore centre near London, expects to invest GBP 25 mn

Mphasis is expanding its footprint in the UK with a special focus on digital transformation initiatives in banking & insurance, by establishing a near shore centre, outside of London. Mphasis expects to create close to 1000 UK jobs to begin with; invest over GBP 25 million upfront towards establishing the centre, and provide up skill and training in both digital transformation as well as domain expertise in the UK banking & insurance segments. Trade and investment between the UK and India is creating good jobs and sustaining livelihoods in both of our countries. It very pleased that Mphasis has decided to join the legions of Indian companies investing in the UK, boosting our tech sector, and driving economic growth.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com